BUPA Global and other private health insurers have approved reimbursement for OncoDNA's test, which is intended to provide a complete genetic profile of a patient's tumor.
Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The kit detects 29 mutations in exons 18, 19, 20, and 21, and has a limit of mutation detection at .1 percent in a background of wild-type DNA.
The university's new court documents allege that Life Tech, its co-plaintiff in the previous suit, "fraudulently" induced it to settle the case against Illumina.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
A study presented at the National Society of Genetic Counselors meeting examined experiences of parents whose children underwent exome sequencing.
Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer enrolled in a Cleveland Clinic study.
RPRD will expand the availability of its PGx testing services to South Korea, and Orient Bio will diversify its business to include precision medicine and clinical PGx.
PerkinElmer Genetics will provide clinical whole-genome sequencing, data interpretation, and diagnostic reports to IDG for patients with neurological disorders.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.
The two firms will offer their technologies and services to patients in Hong Kong, Japan, and Macau to improve drug dosing and prescriptions.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
The firm will hold the intellectual property for its cell capture and analysis technology as QMUL files patents for recent findings using the Parsortix system.
Swiss genomic analytics and AI firm Sophia Genetics has closed on a $30 million Series D round, led by new investor Balderton Capital.
Genome Medical will use the platform for ongoing examination of patients' genomic data to augment data analysis, annotation, and interpretation.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
The institute will provide gene editing services and genetically modified cell lines to Analytical Biological Services.
The deals will expand the availability of Admera's pharmacogenomics testing services to markets including Singapore, Hong Kong, Korea, and Taiwan.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.